REDWOOD CITY, Calif.--(BUSINESS WIRE)--Graybug Vision, Inc., a clinical stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (wet AMD) and primary open angle glaucoma (glaucoma), today announced that Jeffrey L. Cleland, Ph.D., President and CEO, will be presenting at the following upcoming industry conferences:
-
Cowen
and Company 38th Annual Health Care Conference
The Boston Marriott Copley Place, Boston, MA
Monday, March 12 at 1:30pm ET
-
Oppenheimer
28th Annual Healthcare Conference
The Westin New York Grand Central, New York, NY
Wednesday, March 21 at 8:50am ET
-
Needham
17th Annual Healthcare Conference
The Westin New York Grand Central, New York, NY
Wednesday, March 28 at 2:00pm ET
Jeffrey L. Cleland, PhD., President and CEO, will present a corporate overview focused on Graybug Vision’s leading product candidates, GB-102, for the treatment of wet AMD, and potentially best-in-class preclinical glaucoma candidate.
GB-102 is targeted to become a potentially twice per year treatment of wet AMD, representing a significant reduction in frequency of dosing associated with currently available wet AMD therapies. GB-102 is a novel injectable depot formulation intended to gradually release a compound that blocks angiogenesis pathways through multiple receptors (e.g., VEGFR receptors.) Dr. Cleland noted, “We are excited by the progress of our Phase 1/2 study of GB-102 as we are on track to complete enrollment of Phase 1 by the end of Q2 2018, and to present our data at a scientific conference in Q4 2018.” Graybug Vision is also developing a second-generation product in Wet AMD, GB-103, another novel injectable depot formulation with the potential to be a once per year treatment of wet AMD. Preclinical data on GB-103 will be presented at ARVO 2018.
Graybug Vision has generated preclinical data on a potential best-in-class glaucoma agent to provide greater than 40% sustained intraocular pressure (IOP) reduction for up to 6 months after a single injection. Graybug Vision’s novel approach to glaucoma leverages its depot delivery technology platform to enable significantly less frequent dosing along with its novel prodrug technology to create proprietary compounds. Currently, the most common treatment of glaucoma is the use of eye drops that must be taken every day, and patients frequently have difficulty administering or remembering to administer these eye drops. Reduction in elevated IOP is the only proven treatment to reduce progression of glaucoma, and currently available treatments achieve up to approximately 30% IOP lowering.
About Wet Age-related Macular Degeneration (wet AMD)
Wet (neovascular) age-related macular degeneration, is the leading cause of blindness in the developed world in individuals aged 50 years or older. It is caused by the formation of abnormal and leaky new blood vessels behind the retina, termed choroidal neovascularization. The leakage of fluid and protein from the vessels, causes retinal degeneration and leads to severe and rapid loss of vision. According to the National Eye Institute, the prevalence of wet AMD among adults 40 years or older in the U.S. alone is estimated at 1.75 million people. In addition, more than 200,000 new cases are diagnosed annually in the U.S.
About Primary Open Angle Glaucoma (glaucoma)
Primary Open Angle Glaucoma is a leading cause of blindness worldwide. In glaucoma, a clear fluid (called aqueous humor) in the front of the eye passes too slowly through the meshwork drain in the open angle where the cornea and iris meet, causing the fluid to build up and increasing the intraocular pressure (IOP) in the eye. Several large studies have shown that elevated eye pressure is a major risk for damaging the optic nerve. When the optic nerve is damaged from increased pressure, vision loss may result.
About Graybug Vision
Graybug Vision is a clinical stage pharmaceutical company developing novel products for the treatment of ocular diseases. The company’s proprietary injectable products are designed to enable less frequent administration to reduce the burden of treatment for patients and their physicians. The company’s lead clinical-stage injectable product, GB-102, has the potential for twice per year dosing to treat patients with neovascular wet age related macular degeneration (wet AMD). Graybug Vision has also developed a library of preclinical compounds to treat primary open angle glaucoma including a potential best-in-class glaucoma agent with the potential to provide greater than 40% sustained intraocular pressure (IOP) reduction for up to 6 months after a single injection. For more information, please visit www.graybug.com.
